Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced the presentation of preclinical data on CID-078 at the ...

CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with ...

A novel machine learning model enhances colorectal cancer (CRC) prognosis and immunotherapy response prediction by ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, was host to a kidney and bladder cancers oral abstract session. Dr. Tian Zhang discussed the ...

BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

ImmuneOncia Therapeutics, Inc. (CEO Heung-Tae Kim) announced interim results today from the ongoing Phase 1b clinical trial of its next-generation CD47-targeting antibody, IMC-002, in combination with ...

For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...

BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review meeting com ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.